Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.

Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. 

The phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. The lead compound LB-100 is in Phase I trial and has the potential to be first-in-class. 

The deacetylase inhibitors have anti-cancer activity and in model systems correct enzymes deficiencies underlying several inborn metabolic diseases including Gaucher and von Hippel-Lindau disease and neurofibromatosis type 2. 

Lixte's cancer drug development strategy has led to the discovery of novel compounds with the potential to be therapeutically useful against several other important but seemingly disparate diseases. The phosphatase inhibitors are in pre-clinical development for reducing the extent of tissue damage following stroke, heart attack, and septic shock; and, the deacetylase inhibitors for prevention and treatment of neurodegenerative diseases, traumatic brain injury, and topically for fungal dermatitis .

This morning we announced that our lead clinical compound, LB-100, can kill cancer cells through hyper-stimulation of cell proliferation signals in pre-clinical models, according to a report published in Cold Spring Harbor Laboratory's bioRxiv titled, “Paradoxical activation of oncogenic signaling as a cancer treatment strategy.” Click the graphic to read comments from the report's co-author and Lixte's CEO, John Kovach, MD, on how the data suggests that paradoxical activation of oncogenic signaling can result in tumor suppressive resistance. #LB100 #cancer #hyperstimulation #Lixte #BixRxiv 

https://lnkd.in/gNnwzmns

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue			200K -
cost of revenue
gross profit			200K -
selling and marketing expenses
general and administrative expenses	494.96K -	1.29M 159.65%	754.44K 41.30%	833.78K 10.52%	1.34M 61.02%	2.10M 56.22%	1.67M 20.42%	2.01M 20.36%	4.98M 148.07%	4.96M 0.43%
selling general and administrative expenses	494.96K -	1.29M 159.65%	754.44K 41.30%	833.78K 10.52%	1.34M 61.02%	2.10M 56.22%	1.67M 20.42%	2.01M 20.36%	4.98M 148.07%	4.96M 0.43%	4.19M 15.52%
research and development expenses	879.89K -	1.12M 27.06%	2.09M 87.12%	1.30M 37.80%	467.26K 64.09%	40.70K 91.29%	820.91K 1,916.82%	1.22M 49.06%	1.74M 41.93%	1.35M 22.31%	898.10K 33.44%
other expenses		74K -						33.81K -
cost and expenses	1.37M -	2.40M 74.79%	2.85M 18.45%	2.13M 25.00%	1.81M 15.23%	2.14M 18.14%	2.49M 16.46%	3.27M 31.18%	6.72M 105.74%	6.31M 6.09%	5.09M 19.35%
operating expenses	1.37M -	2.40M 74.79%	2.85M 18.45%	2.13M 25.00%	1.81M 15.23%	2.14M 18.14%	2.49M 16.46%	3.27M 31.18%	6.72M 105.74%	6.31M 6.09%	5.09M 19.35%
interest expense	3 -	66 2,100%	78 18.18%	183 134.62%	1.38K 651.37%	4.92K 258.04%		3.67K -	7.41K 101.80%	8.88K 19.71%	-16.23K 282.91%
ebitda	-1.37M -	-2.04M 48.38%	-2.44M 19.64%	-2.13M 12.53%	-1.81M 15.23%	-2.14M 18.14%	-2.49M 16.46%	-3.26M 30.97%	-6.72M 106.05%	-6.30M 6.24%	-5.09M 19.21%
operating income	-1.37M -	-2.40M 74.79%	-2.65M 10.12%	-2.13M 19.33%	-1.81M 15.23%	-2.14M 18.14%	-2.49M 16.46%	-3.27M 31.18%	-6.72M 105.74%	-6.31M 6.09%	-5.09M 19.35%
depreciation and amortization	3 -	363.11K 12,103,600%	205.77K 43.33%			9.85K -	2.49K 74.71%	5.23K 110.11%	626 88.04%	11.20K 1,688.34%
total other income expenses net	3 -	-363.11K 12,103,800%	-205.77K 43.33%	183 100.09%	1.38K 651.37%	4.92K 258.04%	49.72K 910.01%	1.56K 96.87%	-7.95K 610.33%	-1.05K 86.74%	3.21K 404.65%
income before tax	-1.37M -	-2.77M 101.20%	-2.85M 3.11%	-2.13M 25.15%	-1.81M 15.29%	-2.13M 17.96%	-2.44M 14.40%	-3.26M 33.79%	-6.73M 106.08%	-6.31M 6.18%	-5.09M 19.41%
income tax expense		-66 -	-78 18.18%			-9.85K -	-49.72K 405.01%	-1.56K 96.87%	6.79K 535.69%	-7.82K 215.22%
net income	-1.37M -	-2.77M 101.20%	-2.85M 3.11%	-2.13M 25.15%	-1.81M 15.29%	-2.13M 17.96%	-2.39M 12.07%	-3.26M 36.51%	-6.74M 106.39%	-6.30M 6.39%	-5.09M 19.31%
weighted average shs out	693K -	740K 6.78%	779K 5.27%	797K 2.31%	930K 16.69%	979.93K 5.37%	1.12M 14.03%	1.13M 0.92%	1.35M 19.48%	158.20K 88.26%	1.92M 1,111.01%
weighted average shs out dil	693.05K -	740.09K 6.79%	779.89K 5.38%	797.93K 2.31%	930.29K 16.59%	979.93K 5.34%	1.12M 14.03%	1.13M 0.92%	1.35M 19.48%	158.20K 88.26%	1.92M 1,111.01%
eps	-1.98 -	-3.74 88.89%	-3.66 2.14%	-2.68 26.78%	-1.94 27.61%	-2.18 12.37%	-2.14 1.83%	-2.89 35.05%	-5 73.01%	-39.85 697.00%	-2.66 93.32%
epsdiluted	-1.98 -	-3.74 88.89%	-3.66 2.14%	-2.68 26.78%	-1.94 27.61%	-2.18 12.37%	-2.14 1.83%	-2.89 35.05%	-5 73.01%	-39.85 697.00%	-2.66 93.32%

NASDAQ:LIXT

Lixte Biotechnology Holdings, Inc.

Last Close

2.31

26/07 20:00

Market Cap

5.08M

Beta: −0.30

Volume Today

9.06K

Avg: 443.13K

PE Ratio

−0.76

PFCF: −1.01

Preview